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1   SCOPE  OF  TH E  TH ES IS
It is estimated that in the Netherlands between 235,000 and 285,000 subjects are
diagnosed with non-insulin-dependent diabetes mellitus (NIDDM), with possibly
an equal number of patients not diagnosed yet.1-5 Increasing alertness of the
medical profession will lead to earlier diagnosis. The absolute number of
patients will definitely rise in the future, since life expectancy and the number of
elderly people are increasing 6, thus the need for health care will increase.
The Diabetes Control and Complications Trial (DCCT) showed that in patients
with insulin-dependent diabetes mellitus (IDDM) strict blood glucose control
effectively delays the onset and retards the progression of diabetic microvascular
complications such as retinopathy, nephropathy, and neuropathy.7 It is generally
assumed that adequate glycemic control will delay or prevent the development
of chronic complications in NIDDM as well, which is recently confirmed for
microvascular complications in a randomized study in Japan.8 It is also expected
that strict glycemic control in NIDDM has a beneficial impact on macrovascular
complications. However, recently the feasibility trial of the Veterans Affairs
Cooperative Study of Glycemic Control and Complications in Type II Diabetes
(VACSDM) Group suggested that patients in the intensive treated arm are at a
higher risk for cardiovascular events compared to patients in the standard
treatment group.9 It is expected that the United Kingdom Prospective Diabetes
Study (UKPDS), a randomized controlled trial which compares treatment
modalities in more than 5000 newly diagnosed NIDDM patients, and longer
follow-up of the Veterans Affairs Cooperative Study of Diabetes Mellitus will
give more conclusive answers on the pros and cons of strict glycemic control in
NIDDM patients.9-13
In summary, the rise of the absolute number of NIDDM patients and the
growing importance of strict glycemic control implies that in future more
patients will be switched over to insulin therapy.
CHAPTER  1
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In the Netherlands, there is a great demand for evidence-based, practical
treatment protocols, especially concerning insulin treatment. The national
guidelines of the Dutch College of General Practitioners in 1989 for treatment of
NIDDM patients (‘NHG-standaard’), was released in 1989.14,15 However, the
national guidelines do not give any indication how NIDDM patients should be
treated when dietary measures and oral hypoglycemic agents (OHA) treatment
are insufficient according to the general practitioner (GP), and insulin therapy
should be considered.
Whether insulin-treated NIDDM patients should or can be treated in a primary
care setting is also a point of discussion.16,17 In the Zwolle region we have
argued since a decade, that as long as there is a good protocol and sufficient
backup, insulin treatment in NIDDM can be taken care of in a primary care
setting just as well as in a secondary health care facility. Switching over to insulin
is done by a diabetes team in a secondary care facility, and patients are
discharged to primary care as soon as stabilization in glucose reduction is
reached.18
The study described in this thesis examines the patient characteristics of NIDDM
patients who were referred from a primary care setting to our outpatient
department (OPD) of Hospital de Weezenlanden in Zwolle for consideration of
insulin therapy, and it investigates the subsequent effects of improving glycemic
control according to a standardized protocol on quality of life and
cardiovascular risk factors. Additionally, it evaluates the use of the treatment
protocol and GP as well as patient satisfaction with the diabetes treatment at
the OPD.
2   A IMS  OF  TH E  STU D Y
The purpose of this study was:
1 to study retrospectively the disease characteristics of NIDDM patients at our 
OPD between 1970 and 1992 in whom the use of insulin therapy was considered;
2 to study prospectively the diabetes and sociodemographic characteristics of a 
new cohort of NIDDM patients referred by general practitioners for
consideration of insulin therapy and relate this to the chosen therapy to improve
metabolic control;
3 to evaluate the reliability and validity of a new diabetes-specific quality of life
questionnaire: the Diabetes Health Profile;
4 to study prospectively the impact of improvement of metabolic control on 
changes in quality of life in referred NIDDM patients during one year;
5 to study prospectively the impact of improvement of metabolic control on 
INTRODUCT ION
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changes in cardiovascular risk factors in referred NIDDM patients during one
year;
6 to study the maintenance of glycemic control in primary care after discharge 
from the OPD and to evaluate satisfaction of the GP and the patient concerning
the treatment at the OPD.
3   M ETH OD S
Study population
The Zwolle Study included 99 of 113 consecutive NIDDM patients which were
referred to the Outpatient Department of Hospital the Weezenlanden during 18
months (1993 and 1994) by their general practitioners for consideration of
insulin therapy. Refusal, incompetence for giving informed consent, and
insufficient knowledge of the Dutch language were reasons for not participating
in the study. Non-participants did not differ significantly in sex, age at referral,
duration of diabetes or glycated hemoglobin (GHb). Informed consent was
obtained from all the patients. The study was approved by the local ethics
committee.
Treatment protocol
Our treatment protocol is based on national guidelines of the Dutch College of
General Practitioners (’NHG-standaard’)14,15 and a regional protocol (’Zwolse
protocol’), without taking specific age groups into account. The first step in
treatment consisted of visiting the dietician, the diabetes nurse and the
physician who maximized oral therapy. The maximum dosage of diabetes
medication was defined according to the national guidelines: in this protocol
treatment is started with tolbutamide at 500 mg/day (max. 2 g/day). When the
result is unsatisfactory, the medication is replaced by glibenclamide (max. 15
mg/day), gliclazide (max. 240 mg/day) or glipizide max. 20 mg/day. If this
medication also fails, metformin is added (max. 1500 mg/day - officially 2550
mg/day but because of (gastro-intestinal) side-effects physicians generally did
not prescribe more than 1500 mg/day). If maximum oral therapy was insufficient
(poor control according to glucose day curve with glucose > 10 mmol/l), the
patient was switched over to insulin therapy. When the glycemic situation was
stabilized (glucose day curves stable and disappearance of hyperglycemic
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4   OU TL IN E  OF  TH E  TH ES IS
By way of introduction, the background of the research aims are described in
Chapter 2. Chapter 3 contains retrospective data of 495 NIDDM patients at the
OPD in whom the use of insulin therapy was considered. The longitudinal study
described in Chapter 4 presents the characteristics of NIDDM patients referred
for consideration of insulin therapy, evaluates the latest therapy before referral
in respect to the national guidelines, and reports on the chosen therapy to
improve metabolic control in relation with other diabetes characteristics.
Chapter 5 investigates the validity and reliability of a new disease specific
questionnaire, the Diabetes Health Profile, in referred NIDDM patients. Chapter
6 describes the longitudinal study on the association between improvement of
glycemic control and quality of life in referred NIDDM patients. The relation
between improvement of glycemic control and macrovascular risk factors is
presented in Chapter 7. Chapter 8 describes GP and patient satisfaction
concerning the treatment protocol (including switching over to insulin) and the
effect on metabolic control when patients are discharged to their GP. The
general discussion and conclusions as well as recommendations for the future
will be discussed in Chapter 9.
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